MedTrace Logo

A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002

NCT01608711 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2017-05-16

No results posted yet for this study

Summary

The purpose of this study is to continue the safety and immunogenicity of AGS-1C4D4 administered in combination with gemcitabine in subjects previously treated in protocol 2008002.

Conditions

Interventions

BIOLOGICAL

AGS-1C4D4

Intravenous Infusion

BIOLOGICAL

gemcitabine

Intravenous Infusion

Sponsors & Collaborators

  • Agensys, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Agensys, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-07
Primary Completion
2015-11-16
Completion
2015-11-16

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01608711 on ClinicalTrials.gov